董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Cameron Geoffrey McDonough | 男 | Director | 46 | 6.58万美元 | 未持股 | 2017-04-03 |
| Robert J. Perez | 男 | Director | 52 | 6.46万美元 | 未持股 | 2017-04-03 |
| Frances K. Heller | 女 | Director | 50 | 9.25万美元 | 未持股 | 2017-04-03 |
| Frank E. Thomas | 男 | Director | 47 | 7.58万美元 | 未持股 | 2017-04-03 |
| Thomas O. Daniel | 男 | Director | 63 | 7.08万美元 | 未持股 | 2017-04-03 |
| Thomas E. Hughes | 男 | President, Chief Executive Officer and Director | 57 | 250.10万美元 | 未持股 | 2017-04-03 |
| Peter Barrett | 男 | Chairman of the Board | 64 | 9.83万美元 | 未持股 | 2017-04-03 |
| Bruce Booth | 男 | Director | 42 | 8.50万美元 | 未持股 | 2017-04-03 |
| John L. LaMattina | 男 | Director | 67 | 7.33万美元 | 未持股 | 2017-04-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas E. Hughes | 男 | President, Chief Executive Officer and Director | 57 | 250.10万美元 | 未持股 | 2017-04-03 |
| Dennis D. Kim | 男 | Chief Medical Officer | 47 | 104.92万美元 | 未持股 | 2017-04-03 |
| Patricia L. Allen | 女 | Chief Financial Officer | 55 | 95.12万美元 | 未持股 | 2017-04-03 |
董事简历
中英对照 | 中文 | 英文- Cameron Geoffrey McDonough
-
Cameron Geoffrey McDonough自2015年9月起担任公司董事。他自2011年8月起担任Swedish Orphan Biovitrum AB, or Sobi（瑞士一家制药公司）总裁和首席执行官。加入Sobi之前，McDonough从2002年到2011年6月在Genzyme Corporation（一家生物技术公司）担任多个领导职位，包括Personalized Genetic Health高级副总裁和总经理；Lysosomal Storage Disease Therapeutics高级副总裁以及最近担任的欧洲、中东和非洲总裁。加入Genzyme之前，McDonough是一名内科医生和儿科医生。他现任PTC Therapeutics, Inc.（一家公共公司）董事。McDonough持有the University of North Carolina at Chapel Hill文学学士和理学学士学位；Harvard Medical School医学硕士学位。
Cameron Geoffrey McDonough has served as a member of our Board of Directors since September 2015. Since August 2011 he has been President and Chief Executive Officer of Swedish Orphan Biovitrum AB, or Sobi, a Swedish pharmaceutical company. Prior to joining Sobi, Dr. McDonough held several senior leadership positions at Genzyme Corporation, a biotechnology company, from 2002 to June 2011 including Senior Vice President and General Manager, Personalized Genetic Health, Senior Vice President, Lysosomal Storage Disease Therapeutics and most recently, as President of Europe, Middle East and Africa. - Cameron Geoffrey McDonough自2015年9月起担任公司董事。他自2011年8月起担任Swedish Orphan Biovitrum AB, or Sobi（瑞士一家制药公司）总裁和首席执行官。加入Sobi之前，McDonough从2002年到2011年6月在Genzyme Corporation（一家生物技术公司）担任多个领导职位，包括Personalized Genetic Health高级副总裁和总经理；Lysosomal Storage Disease Therapeutics高级副总裁以及最近担任的欧洲、中东和非洲总裁。加入Genzyme之前，McDonough是一名内科医生和儿科医生。他现任PTC Therapeutics, Inc.（一家公共公司）董事。McDonough持有the University of North Carolina at Chapel Hill文学学士和理学学士学位；Harvard Medical School医学硕士学位。
- Cameron Geoffrey McDonough has served as a member of our Board of Directors since September 2015. Since August 2011 he has been President and Chief Executive Officer of Swedish Orphan Biovitrum AB, or Sobi, a Swedish pharmaceutical company. Prior to joining Sobi, Dr. McDonough held several senior leadership positions at Genzyme Corporation, a biotechnology company, from 2002 to June 2011 including Senior Vice President and General Manager, Personalized Genetic Health, Senior Vice President, Lysosomal Storage Disease Therapeutics and most recently, as President of Europe, Middle East and Africa.
- Robert J. Perez
-
Robert J. Perez，2014年3月以来一直担任公司董事会成员，自2012年7月Perez先生担任公司总裁兼首席运营官，从2007年至2012年Perez先生担任本公司执行副总裁兼首席运营官。在此之前从2004年到2007年，他是我们的商业运营高级副总裁，从2003年8月至2004年7月，他担任我们的销售和营销高级副总裁。Perez先生在AMAG制药公司（AMAG Pharmaceuticals, Inc.），一家上市的制药公司董事会任职。Perez先生是马萨诸塞州公民学校（the Citizen Schools of Massachusetts），一个致力于为公立学校表现不佳的孩子延长学习时间的非营利性组织顾问委员会成员，是生物医学科学事业项目（the Biomedical Science Careers Program），一个着重增加生物医学及其他科学相关领域少数族裔代表的非盈利性组织的董事，是达纳-法伯癌症研究所（The Dana-Farber Cancer Institute），一个致力于癌症和相关疾病研究的非营利性组织的董事会成员，是加州医疗保健研究所（California Healthcare Institute），一个致力于研究和宣传加利福尼亚州生物医学界政策利益的非营利性组织的董事，提供对董事为。从2006年至2009年Perez先生担任EPIX制药公司（ EPIX Pharmaceuticals, Inc.），一家上市的生物制药公司的董事，在2014年3月，经公司治理和提名委员会（the Corporate Governance and Nominating Committee）提议，任命Perez先生为董事，成为其年度首席执行官继任计划评审的一份子。
Robert J. Perez has served on our Board since January 2018. Mr. Perez has served as the founder and Managing Partner of Vineyard Sound Advisors, a biopharmaceutical advisory firm since August 2015. He served as Chief Executive Officer of Cubist Pharmaceuticals, Inc., a public pharmaceutical development company, from December 2014 until it was acquired by Merck in January 2015. He joined Cubist in August 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin daptomycin for injection. He served as Executive Vice President and Chief Operating Officer from August 2007 to July 2012 and President and Chief Operating Officer from July 2012 to December 2014. Prior to joining Cubist, he served as Vice President of Biogen, Inc.'s CNS business unit from 2001 to 2003 where he was responsible for commercial leadership of an $800 million neurology business unit, and from 1995 to 2001 he held positions of increasing responsibility within Biogen's CNS commercial organization. Mr. Perez currently serves as a member of the board of directors of AMAG Pharmaceuticals, Inc., Cidara Therapeutics, Inc., Zafgen, Inc. and Unum Therapeutics Inc., positions he has held since 2009 2015 2015 and 2018 respectively. Mr. Perez has been the Founder and Chairman of Life Sciences Cares since January 2016 and also has been a member of the Board of Trustees at The Dana Farber Cancer Institute, Inc. since January 2013. Mr. Perez received a B.S. in business from California State University, Los Angeles and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles. - Robert J. Perez，2014年3月以来一直担任公司董事会成员，自2012年7月Perez先生担任公司总裁兼首席运营官，从2007年至2012年Perez先生担任本公司执行副总裁兼首席运营官。在此之前从2004年到2007年，他是我们的商业运营高级副总裁，从2003年8月至2004年7月，他担任我们的销售和营销高级副总裁。Perez先生在AMAG制药公司（AMAG Pharmaceuticals, Inc.），一家上市的制药公司董事会任职。Perez先生是马萨诸塞州公民学校（the Citizen Schools of Massachusetts），一个致力于为公立学校表现不佳的孩子延长学习时间的非营利性组织顾问委员会成员，是生物医学科学事业项目（the Biomedical Science Careers Program），一个着重增加生物医学及其他科学相关领域少数族裔代表的非盈利性组织的董事，是达纳-法伯癌症研究所（The Dana-Farber Cancer Institute），一个致力于癌症和相关疾病研究的非营利性组织的董事会成员，是加州医疗保健研究所（California Healthcare Institute），一个致力于研究和宣传加利福尼亚州生物医学界政策利益的非营利性组织的董事，提供对董事为。从2006年至2009年Perez先生担任EPIX制药公司（ EPIX Pharmaceuticals, Inc.），一家上市的生物制药公司的董事，在2014年3月，经公司治理和提名委员会（the Corporate Governance and Nominating Committee）提议，任命Perez先生为董事，成为其年度首席执行官继任计划评审的一份子。
- Robert J. Perez has served on our Board since January 2018. Mr. Perez has served as the founder and Managing Partner of Vineyard Sound Advisors, a biopharmaceutical advisory firm since August 2015. He served as Chief Executive Officer of Cubist Pharmaceuticals, Inc., a public pharmaceutical development company, from December 2014 until it was acquired by Merck in January 2015. He joined Cubist in August 2003 as Senior Vice President, Sales and Marketing, and led the launch of Cubicin daptomycin for injection. He served as Executive Vice President and Chief Operating Officer from August 2007 to July 2012 and President and Chief Operating Officer from July 2012 to December 2014. Prior to joining Cubist, he served as Vice President of Biogen, Inc.'s CNS business unit from 2001 to 2003 where he was responsible for commercial leadership of an $800 million neurology business unit, and from 1995 to 2001 he held positions of increasing responsibility within Biogen's CNS commercial organization. Mr. Perez currently serves as a member of the board of directors of AMAG Pharmaceuticals, Inc., Cidara Therapeutics, Inc., Zafgen, Inc. and Unum Therapeutics Inc., positions he has held since 2009 2015 2015 and 2018 respectively. Mr. Perez has been the Founder and Chairman of Life Sciences Cares since January 2016 and also has been a member of the Board of Trustees at The Dana Farber Cancer Institute, Inc. since January 2013. Mr. Perez received a B.S. in business from California State University, Los Angeles and an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles.
- Frances K. Heller
-
Frances K. Heller，2008年8月起，她担任商业发展执行副总裁。2003年12月至加入Exelixis， 她担任Novartis AG。的全球研究组织诺华生物医学研究所（Novartis Institutes for Biomedical Research （NIBR））的战略联盟主管。在该职位上，她协商交易，许诺初期资产加快NIBR的药物发现与开发工作。就职于NIBR之前， 2001至2003年，她担任Signature BioScience, Inc.的公司发展与法律事务副总裁，Signature BioScience, Inc.是肿瘤药物研发公司，她监督所有商业发展和法律事项。就职于Signature Bioscience之前，1998至2001ian，她在Celera Genomics担任职位，责任越来越重要，最近担任公司与知识产权顾问和法律部门主管，负责企业与商业交易和基因发现协作。2011年1月起，她担任私人生物技术公司Admimab, LLC的董事会成员。她是加利福尼亚州律师协会（California State Bar）的成员，有美国专利与商标局（United States Patent and Trademark Office）颁发的许可。她在金州州立大学法学院（Golden Gate University School of Law）获得法学博士学位，在美国大学（American University）获得生物硕士学位，在杜兰大学（Tulane University）获得生物学士学位。
Frances K. Heller has agreed to serve on our board of directors immediately upon the effective date of the registration statement of which this prospectus forms a part. For more than 25 years, Ms. Heller has been an executive and director in the pharmaceutical and biotech industries with expertise in business development, strategic transactions, and legal affairs. In this sector, Ms. Heller was most recently Senior Vice President of Business Development at Bristol-Myers Squibb and a Trustee of the Bristol-Myers Squibb Foundation, from 2012 to 2014. In 2015 Ms. Heller founded Good2Go, Inc., an IoT technology company, for which she currently serves as Chair and Chief Executive Officer. Ms. Heller is a member of the board of directors of Affinivax, a private early-stage vaccine company, the Co-Chair of Lava Maex, a non-profit clean water/mobile hygiene organization and is also on the board of advisers at Tulane University. She previously served as a board member of Zafgen, Inc. Nasdaq: ZFGN (currently Larimar Therapeutics, Inc.) from 2014 to 2017. She also previously served as Trustee of the Dana Farber Cancer Institute. Ms. Heller is a member of the California State Bar and is licensed by the U.S. Patent and Trademark Office. Ms. Heller holds a B.S. in Biology from Tulane University, an M.A. in Biology from American University and a J.D. degree from Golden Gate University. - Frances K. Heller，2008年8月起，她担任商业发展执行副总裁。2003年12月至加入Exelixis， 她担任Novartis AG。的全球研究组织诺华生物医学研究所（Novartis Institutes for Biomedical Research （NIBR））的战略联盟主管。在该职位上，她协商交易，许诺初期资产加快NIBR的药物发现与开发工作。就职于NIBR之前， 2001至2003年，她担任Signature BioScience, Inc.的公司发展与法律事务副总裁，Signature BioScience, Inc.是肿瘤药物研发公司，她监督所有商业发展和法律事项。就职于Signature Bioscience之前，1998至2001ian，她在Celera Genomics担任职位，责任越来越重要，最近担任公司与知识产权顾问和法律部门主管，负责企业与商业交易和基因发现协作。2011年1月起，她担任私人生物技术公司Admimab, LLC的董事会成员。她是加利福尼亚州律师协会（California State Bar）的成员，有美国专利与商标局（United States Patent and Trademark Office）颁发的许可。她在金州州立大学法学院（Golden Gate University School of Law）获得法学博士学位，在美国大学（American University）获得生物硕士学位，在杜兰大学（Tulane University）获得生物学士学位。
- Frances K. Heller has agreed to serve on our board of directors immediately upon the effective date of the registration statement of which this prospectus forms a part. For more than 25 years, Ms. Heller has been an executive and director in the pharmaceutical and biotech industries with expertise in business development, strategic transactions, and legal affairs. In this sector, Ms. Heller was most recently Senior Vice President of Business Development at Bristol-Myers Squibb and a Trustee of the Bristol-Myers Squibb Foundation, from 2012 to 2014. In 2015 Ms. Heller founded Good2Go, Inc., an IoT technology company, for which she currently serves as Chair and Chief Executive Officer. Ms. Heller is a member of the board of directors of Affinivax, a private early-stage vaccine company, the Co-Chair of Lava Maex, a non-profit clean water/mobile hygiene organization and is also on the board of advisers at Tulane University. She previously served as a board member of Zafgen, Inc. Nasdaq: ZFGN (currently Larimar Therapeutics, Inc.) from 2014 to 2017. She also previously served as Trustee of the Dana Farber Cancer Institute. Ms. Heller is a member of the California State Bar and is licensed by the U.S. Patent and Trademark Office. Ms. Heller holds a B.S. in Biology from Tulane University, an M.A. in Biology from American University and a J.D. degree from Golden Gate University.
- Frank E. Thomas
-
Frank E. Thomas，在2011年8月加入Spero Therapeutics, Inc.，担任Spero Therapeutics, Inc.的执行副总裁、首席财务官和财务主管，目前担任执行副总裁兼首席运营官。从2011年11月至2012年5月，他还担任临时董事长和首席执行官。在加入Spero Therapeutics, Inc.之前，从2008年10月到2011年7月，他担任Molecular Biometrics商业阶段医疗诊断公司的高级副总裁、首席运营官和首席财务官。加入Molecular Biometrics之前，从2004年4月到2008年3月，他在Critical Therapeutics公共生物制药公司任职4年， 2006年6月，他被提升为总裁兼首席执行官，2006年12月，担任高级副总裁兼首席财务官。从2006年到2008年，他担任Critical Therapeutics的董事会主席。2004年之前，他担任Esperion Therapeutics生物制药公司的首席财务官和金融投资副董事长。自2007年起，他一直担任麻萨诸塞州生物技术委员会的董事会成员。他持有安娜堡密歇根大学的商业管理学士学位。
Frank E. Thomas,has served on Spero Therapeutics, Inc. Board of Directors since July 2017. Mr. Thomas is currently President and Chief Operating Officer of Orchard Therapeutics, a development-stage biotechnology company based in the United Kingdom, where he served as Chief Financial Officer and Chief Business Officer from January 2018 to March 2020. Prior to Orchard, Mr. Thomas served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a commercial-stage pharmaceutical company, which was a publicly traded company that was subsequently acquired by Covis Pharma, from April 2015 to April 2017, as AMAG's Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and as Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., which was a publicly traded company that subsequently merged with Cornerstone Therapeutics Inc., from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company (Nasdaq: ESPR). Mr. Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015. Mr. Thomas currently serves as a member of the board of directors of Larimar Therapeutics Inc (Nasdaq: LRMR). Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor. - Frank E. Thomas，在2011年8月加入Spero Therapeutics, Inc.，担任Spero Therapeutics, Inc.的执行副总裁、首席财务官和财务主管，目前担任执行副总裁兼首席运营官。从2011年11月至2012年5月，他还担任临时董事长和首席执行官。在加入Spero Therapeutics, Inc.之前，从2008年10月到2011年7月，他担任Molecular Biometrics商业阶段医疗诊断公司的高级副总裁、首席运营官和首席财务官。加入Molecular Biometrics之前，从2004年4月到2008年3月，他在Critical Therapeutics公共生物制药公司任职4年， 2006年6月，他被提升为总裁兼首席执行官，2006年12月，担任高级副总裁兼首席财务官。从2006年到2008年，他担任Critical Therapeutics的董事会主席。2004年之前，他担任Esperion Therapeutics生物制药公司的首席财务官和金融投资副董事长。自2007年起，他一直担任麻萨诸塞州生物技术委员会的董事会成员。他持有安娜堡密歇根大学的商业管理学士学位。
- Frank E. Thomas,has served on Spero Therapeutics, Inc. Board of Directors since July 2017. Mr. Thomas is currently President and Chief Operating Officer of Orchard Therapeutics, a development-stage biotechnology company based in the United Kingdom, where he served as Chief Financial Officer and Chief Business Officer from January 2018 to March 2020. Prior to Orchard, Mr. Thomas served as the President and Chief Operating Officer of AMAG Pharmaceuticals, Inc., a commercial-stage pharmaceutical company, which was a publicly traded company that was subsequently acquired by Covis Pharma, from April 2015 to April 2017, as AMAG's Executive Vice President and Chief Operating Officer from May 2012 through April 2015 and as Executive Vice President, Chief Financial Officer and Treasurer from August 2011 through May 2012. Prior to AMAG, he served as Senior Vice President, Chief Operating Officer and Chief Financial Officer for Molecular Biometrics, Inc., a commercial-stage medical diagnostics company, from October 2008 to July 2011. Prior to Molecular Biometrics, Mr. Thomas spent four years at Critical Therapeutics, Inc., which was a publicly traded company that subsequently merged with Cornerstone Therapeutics Inc., from April 2004 to March 2008, where he was promoted to President in June 2006 and Chief Executive Officer in December 2006 from the position of Senior Vice President and Chief Financial Officer. He also served on the board of directors of Critical Therapeutics from 2006 to 2008. Prior to 2004, Mr. Thomas served as the Chief Financial Officer and Vice President of Finance and Investor Relations at Esperion Therapeutics, Inc., a public biopharmaceutical company (Nasdaq: ESPR). Mr. Thomas was a member of the board of directors of the Massachusetts Biotechnology Council from 2007 to 2015. Mr. Thomas currently serves as a member of the board of directors of Larimar Therapeutics Inc (Nasdaq: LRMR). Mr. Thomas holds a B.B.A. from the University of Michigan, Ann Arbor.
- Thomas O. Daniel
-
Thomas O. Daniel自2006年12月起任命为负责研究和早期发展的总裁；2012年2月15日起担任负责研究和早期发展的执行副总裁及总裁。自2003年9月起，他在Ambrx公司（一家致力于开发蛋白质治疗的生物技术公司）担任首席科学官和董事。他还在Amgen公司担任副总裁，在那里他是Amgen华盛顿研究网站的负责人及炎症治疗领域的负责人。在Amgen公司收购Immunex公司之前，他还担任负责开发研究的高级副总裁。自2011年3月1日起，他一直aTyr制药公司的治疗顾问委员会的成员，是Ferrumax公司和Epizyme公司（两家都是私有的生物科技公司）的董事。他还是范德比尔特大学医学中心生物医学科学顾问委员会的成员。作为一名肾脏科医师和前学术研究者，他曾是范德堡大学公里医学和细胞生物学的K.M. Hakim教授，范德比尔特中心血管生物学的主任。此前，他曾在加州大学旧金山分校的霍华德休斯医学研究所进行研究，在德克萨斯大学获得硕士学位，在美国马萨诸塞州总医院完成住院医师。
Thomas O. Daniel has served as a member of our Board of Directors since October 2016. Dr. Daniel has 20 years of experience in biopharmaceutical discovery and development. He is currently Chairman of Locana Inc., is a venture partner at ARCH Venture Partners, Inc., and is a director at Larimar Therapeutics, Inc. formerly Zafgen, Inc. until the completion of its merger with Chondrial Therapeutics, Inc. in May 2020 and Gossamer Bio, Inc. He was recently Chairman of Research at Celgene Corporation, and served as President of Research and Early Development from December 2006 until February 2012 and as Executive Vice President and President of Research and Early Development until December 2015. Previously, he served as Chief Scientific Officer and Director at Ambrx Inc., from August 2003 to November 2006. Dr. Daniel also served as Vice President of Research at Amgen Inc. from August 2002 to April 2003 where he was Research Site Head of Amgen Washington and Therapeutic Area Head of Inflammation. Prior to Amgen Inc.'s acquisition of Immunex Corporation, Dr. Daniel served as Senior Vice President of Discovery Research at Immunex Corporation from May 2000 to August 2002. Dr. Daniel previously served on the boards of Juno Therapeutics, Inc. from July 2015 to March 2018 and Epizyme, Inc. from May 2013 to June 2014. Dr. Daniel is a Trustee of Reed College, serves on the Board of the Alliance for Lupus Research, and advises privately-held biotechnology companies including Brii Biosciences Limited, Epirium Bio, Inc. and BlackThorn Therapeutics. Dr. Daniel serves as Chairman of the Board of Overseers of The Scripps Research Institute and on the Biomedical Science Advisory Board of Vanderbilt University Medical Center. A nephrologist and former academic investigator, Dr. Daniel was previously the C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University. He formerly conducted research in the Howard Hughes Medical Institute at UC San Francisco, earned an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital. - Thomas O. Daniel自2006年12月起任命为负责研究和早期发展的总裁；2012年2月15日起担任负责研究和早期发展的执行副总裁及总裁。自2003年9月起，他在Ambrx公司（一家致力于开发蛋白质治疗的生物技术公司）担任首席科学官和董事。他还在Amgen公司担任副总裁，在那里他是Amgen华盛顿研究网站的负责人及炎症治疗领域的负责人。在Amgen公司收购Immunex公司之前，他还担任负责开发研究的高级副总裁。自2011年3月1日起，他一直aTyr制药公司的治疗顾问委员会的成员，是Ferrumax公司和Epizyme公司（两家都是私有的生物科技公司）的董事。他还是范德比尔特大学医学中心生物医学科学顾问委员会的成员。作为一名肾脏科医师和前学术研究者，他曾是范德堡大学公里医学和细胞生物学的K.M. Hakim教授，范德比尔特中心血管生物学的主任。此前，他曾在加州大学旧金山分校的霍华德休斯医学研究所进行研究，在德克萨斯大学获得硕士学位，在美国马萨诸塞州总医院完成住院医师。
- Thomas O. Daniel has served as a member of our Board of Directors since October 2016. Dr. Daniel has 20 years of experience in biopharmaceutical discovery and development. He is currently Chairman of Locana Inc., is a venture partner at ARCH Venture Partners, Inc., and is a director at Larimar Therapeutics, Inc. formerly Zafgen, Inc. until the completion of its merger with Chondrial Therapeutics, Inc. in May 2020 and Gossamer Bio, Inc. He was recently Chairman of Research at Celgene Corporation, and served as President of Research and Early Development from December 2006 until February 2012 and as Executive Vice President and President of Research and Early Development until December 2015. Previously, he served as Chief Scientific Officer and Director at Ambrx Inc., from August 2003 to November 2006. Dr. Daniel also served as Vice President of Research at Amgen Inc. from August 2002 to April 2003 where he was Research Site Head of Amgen Washington and Therapeutic Area Head of Inflammation. Prior to Amgen Inc.'s acquisition of Immunex Corporation, Dr. Daniel served as Senior Vice President of Discovery Research at Immunex Corporation from May 2000 to August 2002. Dr. Daniel previously served on the boards of Juno Therapeutics, Inc. from July 2015 to March 2018 and Epizyme, Inc. from May 2013 to June 2014. Dr. Daniel is a Trustee of Reed College, serves on the Board of the Alliance for Lupus Research, and advises privately-held biotechnology companies including Brii Biosciences Limited, Epirium Bio, Inc. and BlackThorn Therapeutics. Dr. Daniel serves as Chairman of the Board of Overseers of The Scripps Research Institute and on the Biomedical Science Advisory Board of Vanderbilt University Medical Center. A nephrologist and former academic investigator, Dr. Daniel was previously the C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University. He formerly conducted research in the Howard Hughes Medical Institute at UC San Francisco, earned an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital.
- Thomas E. Hughes
-
Thomas E. Hughes， 博士学位。自2008年10月起担任首席执行官、总裁和董事。1987年到2008年在 Novartis AG （原先被称为Sandoz Pharmaceuticals）担任多个职位，包括担任位于马塞诸塞特州剑桥的the Novartis Institutes for BioMedical Research副总裁和心血管疾病和代谢性疾病治疗领域全球主管。在他担任这些职位期间，他监管很多针对肥胖症，糖尿病和心脏疾病的药物发现和开发项目。他是40多篇同行杂志出版物的作者，也是有关治疗糖尿病，心血管疾病和肥胖症的已发行及正在申请的专利的发明者。他还担任 Miragen Therapeutics, Inc.董事，并且是多个科学和战略顾问委员会成员，包括Broadview Ventures and Nimbus Discovery, LLC.。他持有Tufts University营养生物化学博士学位；Virginia Polytechnic Institute & State University动物学硕士学位以及Franklin and Marshall College生物学学士学位。
Thomas E. Hughes has served as a member of our Board of Directors since February 2017 and, prior to joining our Board of Directors, he served as a member of Private Miragen’s board of directors since September 2009. Dr. Hughes serves as chief executive officer and as a director of Navitor Pharmaceuticals, Inc., a privately held biopharmaceutical company, having joined the company in September 2018. Prior to that, Dr. Hughes served in varying capacities at Zafgen, Inc., a publicly traded biopharmaceutical company, as the chief executive officer and as a director from October 2008 through October 2017 as president from October 2008 until June 2014 and as chief scientific officer and president from October 2017 through August 2018. From 1987 to 2008 Dr. Hughes held several positions at Novartis AG formerly Sandoz Pharmaceuticals, including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research in Cambridge, MA. Dr. Hughes also serves as a member of the strategic advisory board for Broadview Ventures, an early-stage investment company. Dr. Hughes earned a Ph.D. in nutritional biochemistry from Tufts University, an M.S. in Zoology from Virginia Polytechnic Institute and State University and a B.A. in biology from Franklin and Marshall College. - Thomas E. Hughes， 博士学位。自2008年10月起担任首席执行官、总裁和董事。1987年到2008年在 Novartis AG （原先被称为Sandoz Pharmaceuticals）担任多个职位，包括担任位于马塞诸塞特州剑桥的the Novartis Institutes for BioMedical Research副总裁和心血管疾病和代谢性疾病治疗领域全球主管。在他担任这些职位期间，他监管很多针对肥胖症，糖尿病和心脏疾病的药物发现和开发项目。他是40多篇同行杂志出版物的作者，也是有关治疗糖尿病，心血管疾病和肥胖症的已发行及正在申请的专利的发明者。他还担任 Miragen Therapeutics, Inc.董事，并且是多个科学和战略顾问委员会成员，包括Broadview Ventures and Nimbus Discovery, LLC.。他持有Tufts University营养生物化学博士学位；Virginia Polytechnic Institute & State University动物学硕士学位以及Franklin and Marshall College生物学学士学位。
- Thomas E. Hughes has served as a member of our Board of Directors since February 2017 and, prior to joining our Board of Directors, he served as a member of Private Miragen’s board of directors since September 2009. Dr. Hughes serves as chief executive officer and as a director of Navitor Pharmaceuticals, Inc., a privately held biopharmaceutical company, having joined the company in September 2018. Prior to that, Dr. Hughes served in varying capacities at Zafgen, Inc., a publicly traded biopharmaceutical company, as the chief executive officer and as a director from October 2008 through October 2017 as president from October 2008 until June 2014 and as chief scientific officer and president from October 2017 through August 2018. From 1987 to 2008 Dr. Hughes held several positions at Novartis AG formerly Sandoz Pharmaceuticals, including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research in Cambridge, MA. Dr. Hughes also serves as a member of the strategic advisory board for Broadview Ventures, an early-stage investment company. Dr. Hughes earned a Ph.D. in nutritional biochemistry from Tufts University, an M.S. in Zoology from Virginia Polytechnic Institute and State University and a B.A. in biology from Franklin and Marshall College.
- Peter Barrett
-
Peter Barrett，2002年加入早期生命科学风险投资基金Atlas Venture，是生命科学集团的合伙人，曾参与创建多家治疗和药物发现平台公司。此前，他是Celera Genomics的联合创始人、执行副总裁兼首席商务官，该公司于2001年宣布首次成功进行人类基因组测序。在此之前，Barrett博士曾在Perkin-Elmer公司担任多个高级管理职位，最近担任企业规划和业务发展副总裁，在那里他经营着多项业务，并通过一系列许可协议、合作伙伴关系和收购帮助大幅扩展其生命科学产品组合。他目前担任上市公司Synlogic, Inc.的董事长，并且是私人控股的Obsidian Therapeutics，Inc.的董事会成员。Barrett博士还是哈佛商学院的执行研究员，并且是Blavatnik Fellowship项目关键顾问委员会的主席。Barrett博士在洛厄尔技术学院（现称马萨诸塞大学洛厄尔分校）获得化学理学学士学位，并在东北大学获得分析化学博士学位。
Peter Barrett,joined Atlas Venture, an early-stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group, where he has been involved in the creation of several therapeutic and drug discovery platform companies. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics which in 2001 announced the first successful sequencing of the human genome. Prior to that, Dr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development, where he operated several businesses and helped to greatly expand its life sciences portfolio through a series of licensing agreements, partnerships and acquisitions. He currently serves as the Chairman of Synlogic, Inc., which is publicly traded, and is a board member of privately held Obsidian Therapeutics, Inc. Dr. Barrett is also an executive fellow at the Harvard Business School and is the chair of the key advisory board of the Blavatnik Fellowship program. Dr. Barrett previously served on the board of Larimar Therapeutics, Inc., a publicly traded company, until 2023. In addition, Dr. Barrett is a board member of Nucleate, a student run non-profit organization representing the global community of bio-innovators. Dr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his doctoral degree in analytical chemistry from Northeastern University. - Peter Barrett，2002年加入早期生命科学风险投资基金Atlas Venture，是生命科学集团的合伙人，曾参与创建多家治疗和药物发现平台公司。此前，他是Celera Genomics的联合创始人、执行副总裁兼首席商务官，该公司于2001年宣布首次成功进行人类基因组测序。在此之前，Barrett博士曾在Perkin-Elmer公司担任多个高级管理职位，最近担任企业规划和业务发展副总裁，在那里他经营着多项业务，并通过一系列许可协议、合作伙伴关系和收购帮助大幅扩展其生命科学产品组合。他目前担任上市公司Synlogic, Inc.的董事长，并且是私人控股的Obsidian Therapeutics，Inc.的董事会成员。Barrett博士还是哈佛商学院的执行研究员，并且是Blavatnik Fellowship项目关键顾问委员会的主席。Barrett博士在洛厄尔技术学院（现称马萨诸塞大学洛厄尔分校）获得化学理学学士学位，并在东北大学获得分析化学博士学位。
- Peter Barrett,joined Atlas Venture, an early-stage life sciences venture capital fund, in 2002 and is a partner in the life sciences group, where he has been involved in the creation of several therapeutic and drug discovery platform companies. Previously, he was a co-founder, Executive Vice President and Chief Business Officer of Celera Genomics which in 2001 announced the first successful sequencing of the human genome. Prior to that, Dr. Barrett held several senior management positions at The Perkin-Elmer Corporation, most recently serving as Vice President, Corporate Planning and Business Development, where he operated several businesses and helped to greatly expand its life sciences portfolio through a series of licensing agreements, partnerships and acquisitions. He currently serves as the Chairman of Synlogic, Inc., which is publicly traded, and is a board member of privately held Obsidian Therapeutics, Inc. Dr. Barrett is also an executive fellow at the Harvard Business School and is the chair of the key advisory board of the Blavatnik Fellowship program. Dr. Barrett previously served on the board of Larimar Therapeutics, Inc., a publicly traded company, until 2023. In addition, Dr. Barrett is a board member of Nucleate, a student run non-profit organization representing the global community of bio-innovators. Dr. Barrett received his Bachelor of Science degree in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and his doctoral degree in analytical chemistry from Northeastern University.
- Bruce Booth
-
Bruce Booth，自2020年6月起担任Sionna Therapeutics， Inc.董事会成员。Booth博士于2005年加入Atlas Venture，目前担任普通合伙人。他还曾担任武田制药有限公司（纽约证券交易所代码：TAK）、UCB生物制药公司和比尔和梅林达盖茨基金会的各种顾问。Booth博士是Kymera的联合创始人，并自2016年4月起担任其董事会主席。他还担任Vigil Neuroscience， Inc.（纳斯达克股票代码：Vigil）的董事长（2020年6月以来）。他是几家私人公司的主席或董事会成员，包括Nimbus Therapeutics， LLC, HotSpot Therapeutics, Inc., Arkuda Therapeutics, Inc.和Matchpoint Therapeutics， Inc.。他曾于2016年2月至2024年6月担任AVROBIO， Inc.（现为Tectonic Therapeutic， Inc. （NASDAQ： TECX））， 2016年2月至2023年9月担任Magenta Therapeutics， Inc.（现为Dianthus Therapeutics， Inc. （NASDAQ： DNTH））， 2014年10月至2020年7月担任Unum Therapeutics， Inc.（现为Cogent Biosciences， Inc. （NASDAQ： COGT））和几家私人公司的董事会成员。Booth博士以优异成绩获得宾夕法尼亚州立大学（Pennsylvania State University）生物化学学士学位。布斯博士是英国马歇尔学者，并获得了哲学博士学位。来自牛津大学纳菲尔德医学系的分子免疫学博士。
Bruce Booth,has served as Chairman of board of directors and has been a member of board of directors since September 2015. Dr. Booth was co-founder, President and Chief Executive Officer from September 2015 to August 2017. Dr. Booth joined Atlas Venture in 2005, and currently serves as a partner of Atlas Venture. Previously, from 2004 to 2005, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm's venture capital activities. He currently serves as chair of the board of directors of Vigil Neuroscience, Inc. a publicly traded biotechnology company and as a member of the board of Sionna Therapeutics, Inc. a publicly traded biotechnology company. He also serves as either Chair or member of the board of directors of multiple privately held companies. Dr. Booth holds a D.Phil. in molecular immunology from Oxford University's Nuffield Department of Medicine and a B.S. in biochemistry from Pennsylvania State University. - Bruce Booth，自2020年6月起担任Sionna Therapeutics， Inc.董事会成员。Booth博士于2005年加入Atlas Venture，目前担任普通合伙人。他还曾担任武田制药有限公司（纽约证券交易所代码：TAK）、UCB生物制药公司和比尔和梅林达盖茨基金会的各种顾问。Booth博士是Kymera的联合创始人，并自2016年4月起担任其董事会主席。他还担任Vigil Neuroscience， Inc.（纳斯达克股票代码：Vigil）的董事长（2020年6月以来）。他是几家私人公司的主席或董事会成员，包括Nimbus Therapeutics， LLC, HotSpot Therapeutics, Inc., Arkuda Therapeutics, Inc.和Matchpoint Therapeutics， Inc.。他曾于2016年2月至2024年6月担任AVROBIO， Inc.（现为Tectonic Therapeutic， Inc. （NASDAQ： TECX））， 2016年2月至2023年9月担任Magenta Therapeutics， Inc.（现为Dianthus Therapeutics， Inc. （NASDAQ： DNTH））， 2014年10月至2020年7月担任Unum Therapeutics， Inc.（现为Cogent Biosciences， Inc. （NASDAQ： COGT））和几家私人公司的董事会成员。Booth博士以优异成绩获得宾夕法尼亚州立大学（Pennsylvania State University）生物化学学士学位。布斯博士是英国马歇尔学者，并获得了哲学博士学位。来自牛津大学纳菲尔德医学系的分子免疫学博士。
- Bruce Booth,has served as Chairman of board of directors and has been a member of board of directors since September 2015. Dr. Booth was co-founder, President and Chief Executive Officer from September 2015 to August 2017. Dr. Booth joined Atlas Venture in 2005, and currently serves as a partner of Atlas Venture. Previously, from 2004 to 2005, Dr. Booth was a principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm, where he focused on the firm's venture capital activities. He currently serves as chair of the board of directors of Vigil Neuroscience, Inc. a publicly traded biotechnology company and as a member of the board of Sionna Therapeutics, Inc. a publicly traded biotechnology company. He also serves as either Chair or member of the board of directors of multiple privately held companies. Dr. Booth holds a D.Phil. in molecular immunology from Oxford University's Nuffield Department of Medicine and a B.S. in biochemistry from Pennsylvania State University.
- John L. LaMattina
-
John L. LaMattina，博士，自2011年2月起担任Ligand董事会成员。他在辉瑞公司工作了30年，从1977年开始担任药物化学家。在他的职业生涯中，他被任命为Pfizer Central Research的各种职位，责任日益增加，包括1993年担任美国发现运营副总裁，1998年担任全球发现运营高级副总裁，1999年担任全球开发高级副总裁，2004年担任辉瑞全球研发总裁。LaMattina博士以优异的成绩毕业于Boston College，获得化学学士学位。他获得新罕布什尔大学有机化学博士学位，随后在普林斯顿大学参加美国国立卫生研究院博士后项目。他目前是PureTech Ventures的高级合伙人，并担任PureTech Health、Gelesis和Vedanta的董事会成员。此外，他担任Zafgen， Inc.的董事，也是Trevena的科学顾问委员会成员。
John L. LaMattina, Ph.D., has served as a member of Ligand's board since February 2011. He spent 30 years at Pfizer Inc. beginning as a medicinal chemist in 1977. During his career, he was appointed to various positions of increasing responsibility for Pfizer Central Research, including Vice President of U.S. Discovery Operations in 1993 Senior Vice President of Worldwide Discovery Operations in 1998 Senior Vice President of Worldwide Development in 1999 and President, Pfizer Global R&D in 2004. Dr. LaMattina graduated with cum laude honors from Boston College with a B.S. in Chemistry. He received a Ph.D. from the University of New Hampshire in Organic Chemistry and subsequently was at Princeton University in the National Institutes of Health Postdoctoral Fellowship program. Dr. LaMattina is currently a senior partner at PureTech Ventures and serves on the board of directors of PureTech Health, Gelesis and Vedanta. Additionally, Dr. LaMattina serves as a director of Zafgen, Inc. and is on the Scientific Advisory Board for Trevena. - John L. LaMattina，博士，自2011年2月起担任Ligand董事会成员。他在辉瑞公司工作了30年，从1977年开始担任药物化学家。在他的职业生涯中，他被任命为Pfizer Central Research的各种职位，责任日益增加，包括1993年担任美国发现运营副总裁，1998年担任全球发现运营高级副总裁，1999年担任全球开发高级副总裁，2004年担任辉瑞全球研发总裁。LaMattina博士以优异的成绩毕业于Boston College，获得化学学士学位。他获得新罕布什尔大学有机化学博士学位，随后在普林斯顿大学参加美国国立卫生研究院博士后项目。他目前是PureTech Ventures的高级合伙人，并担任PureTech Health、Gelesis和Vedanta的董事会成员。此外，他担任Zafgen， Inc.的董事，也是Trevena的科学顾问委员会成员。
- John L. LaMattina, Ph.D., has served as a member of Ligand's board since February 2011. He spent 30 years at Pfizer Inc. beginning as a medicinal chemist in 1977. During his career, he was appointed to various positions of increasing responsibility for Pfizer Central Research, including Vice President of U.S. Discovery Operations in 1993 Senior Vice President of Worldwide Discovery Operations in 1998 Senior Vice President of Worldwide Development in 1999 and President, Pfizer Global R&D in 2004. Dr. LaMattina graduated with cum laude honors from Boston College with a B.S. in Chemistry. He received a Ph.D. from the University of New Hampshire in Organic Chemistry and subsequently was at Princeton University in the National Institutes of Health Postdoctoral Fellowship program. Dr. LaMattina is currently a senior partner at PureTech Ventures and serves on the board of directors of PureTech Health, Gelesis and Vedanta. Additionally, Dr. LaMattina serves as a director of Zafgen, Inc. and is on the Scientific Advisory Board for Trevena.
高管简历
中英对照 | 中文 | 英文- Thomas E. Hughes
Thomas E. Hughes， 博士学位。自2008年10月起担任首席执行官、总裁和董事。1987年到2008年在 Novartis AG （原先被称为Sandoz Pharmaceuticals）担任多个职位，包括担任位于马塞诸塞特州剑桥的the Novartis Institutes for BioMedical Research副总裁和心血管疾病和代谢性疾病治疗领域全球主管。在他担任这些职位期间，他监管很多针对肥胖症，糖尿病和心脏疾病的药物发现和开发项目。他是40多篇同行杂志出版物的作者，也是有关治疗糖尿病，心血管疾病和肥胖症的已发行及正在申请的专利的发明者。他还担任 Miragen Therapeutics, Inc.董事，并且是多个科学和战略顾问委员会成员，包括Broadview Ventures and Nimbus Discovery, LLC.。他持有Tufts University营养生物化学博士学位；Virginia Polytechnic Institute & State University动物学硕士学位以及Franklin and Marshall College生物学学士学位。
Thomas E. Hughes has served as a member of our Board of Directors since February 2017 and, prior to joining our Board of Directors, he served as a member of Private Miragen’s board of directors since September 2009. Dr. Hughes serves as chief executive officer and as a director of Navitor Pharmaceuticals, Inc., a privately held biopharmaceutical company, having joined the company in September 2018. Prior to that, Dr. Hughes served in varying capacities at Zafgen, Inc., a publicly traded biopharmaceutical company, as the chief executive officer and as a director from October 2008 through October 2017 as president from October 2008 until June 2014 and as chief scientific officer and president from October 2017 through August 2018. From 1987 to 2008 Dr. Hughes held several positions at Novartis AG formerly Sandoz Pharmaceuticals, including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research in Cambridge, MA. Dr. Hughes also serves as a member of the strategic advisory board for Broadview Ventures, an early-stage investment company. Dr. Hughes earned a Ph.D. in nutritional biochemistry from Tufts University, an M.S. in Zoology from Virginia Polytechnic Institute and State University and a B.A. in biology from Franklin and Marshall College.- Thomas E. Hughes， 博士学位。自2008年10月起担任首席执行官、总裁和董事。1987年到2008年在 Novartis AG （原先被称为Sandoz Pharmaceuticals）担任多个职位，包括担任位于马塞诸塞特州剑桥的the Novartis Institutes for BioMedical Research副总裁和心血管疾病和代谢性疾病治疗领域全球主管。在他担任这些职位期间，他监管很多针对肥胖症，糖尿病和心脏疾病的药物发现和开发项目。他是40多篇同行杂志出版物的作者，也是有关治疗糖尿病，心血管疾病和肥胖症的已发行及正在申请的专利的发明者。他还担任 Miragen Therapeutics, Inc.董事，并且是多个科学和战略顾问委员会成员，包括Broadview Ventures and Nimbus Discovery, LLC.。他持有Tufts University营养生物化学博士学位；Virginia Polytechnic Institute & State University动物学硕士学位以及Franklin and Marshall College生物学学士学位。
- Thomas E. Hughes has served as a member of our Board of Directors since February 2017 and, prior to joining our Board of Directors, he served as a member of Private Miragen’s board of directors since September 2009. Dr. Hughes serves as chief executive officer and as a director of Navitor Pharmaceuticals, Inc., a privately held biopharmaceutical company, having joined the company in September 2018. Prior to that, Dr. Hughes served in varying capacities at Zafgen, Inc., a publicly traded biopharmaceutical company, as the chief executive officer and as a director from October 2008 through October 2017 as president from October 2008 until June 2014 and as chief scientific officer and president from October 2017 through August 2018. From 1987 to 2008 Dr. Hughes held several positions at Novartis AG formerly Sandoz Pharmaceuticals, including vice president and global head of the cardiovascular and metabolic diseases therapeutic area at the Novartis Institutes for BioMedical Research in Cambridge, MA. Dr. Hughes also serves as a member of the strategic advisory board for Broadview Ventures, an early-stage investment company. Dr. Hughes earned a Ph.D. in nutritional biochemistry from Tufts University, an M.S. in Zoology from Virginia Polytechnic Institute and State University and a B.A. in biology from Franklin and Marshall College.
- Dennis D. Kim
Dennis D. Kim， 硕士学位，公司管理硕士学位。自2011年9月起担任公司首席医疗官。2001年到2012年他担任加利佛尼亚大学圣地亚哥分校（the University of California, San Diego ）医学院内分泌学/代谢学系医学教授助理。2008年9月到2011年2月他在 Orexigen Therapeutics（一家生物制药公司）担任多个高级临床和企业事务职位，包括高级副总裁；肥胖/代谢性疾病主管；企业开发高级副总裁；医疗事务和通讯高级副总裁。加入 Orexigen之前，从2007年9月到2008年9月担任 EnteroMedics, Inc.首席医疗官和医疗事务副总裁 ，负责临床事务的所有问题并在2007年以高管团队成员的身份成功地实施首次公开募股。之前从2001年7月到2007年9月他在Amylin Pharmaceuticals, Inc.担任多个职位，最近的职位是担任企业战略执行主管 ，管理企业和业务战略规划，范围涵盖涵盖所有的商业产品，发育候选药物，企业联盟的合作伙伴关系和制造支持。他持有the University of Health Sciences芝加哥医学院（ The Chicago Medical School）硕士学位；加利佛尼亚大学圣地亚哥分校（ University of California, San Diego） Rady管理学院工商管理硕士学位；以及加利佛尼亚大学洛杉矶分校（the University of California at Los Angeles）生物理学学士学位。
Dennis D. Kim has served as our Chief Medical Officer since September 2011. From 2001 to 2012 Dr. Kim was an assistant professor of medicine, division of endocrinology/metabolism, at the University of California, San Diego School of Medicine. From September 2008 to February 2011 Dr. Kim held multiple senior-level clinical and corporate affairs positions at Orexigen Therapeutics, Inc. a publicly-traded biopharmaceutical company focused on the treatment of obesity, including senior vice president, head of obesity/metabolic diseases; senior vice president, corporate development; and senior vice president, medical affairs and communications. Prior to Orexigen, from September 2007 to September 2008 he was chief medical officer and vice president of medical affairs at EnteroMedics, Inc. a publicly traded medical device company, where he oversaw all aspects of clinical affairs and successfully implemented an initial public offering as part of the executive team in 2007. Previously, from July 2001 to September 2007 he held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly traded biotechnology company, most recently as executive director, corporate strategy, where he managed corporate and business strategic planning spanning all commercial products, developmental drug candidates, corporate alliance partnership and manufacturing support. Dr. Kim holds an M.D. from the University of Health Sciences, The Chicago Medical School, an M.B.A from University of California, San Diego Rady School of Management and a B.S. in biology from the University of California at Los Angeles.- Dennis D. Kim， 硕士学位，公司管理硕士学位。自2011年9月起担任公司首席医疗官。2001年到2012年他担任加利佛尼亚大学圣地亚哥分校（the University of California, San Diego ）医学院内分泌学/代谢学系医学教授助理。2008年9月到2011年2月他在 Orexigen Therapeutics（一家生物制药公司）担任多个高级临床和企业事务职位，包括高级副总裁；肥胖/代谢性疾病主管；企业开发高级副总裁；医疗事务和通讯高级副总裁。加入 Orexigen之前，从2007年9月到2008年9月担任 EnteroMedics, Inc.首席医疗官和医疗事务副总裁 ，负责临床事务的所有问题并在2007年以高管团队成员的身份成功地实施首次公开募股。之前从2001年7月到2007年9月他在Amylin Pharmaceuticals, Inc.担任多个职位，最近的职位是担任企业战略执行主管 ，管理企业和业务战略规划，范围涵盖涵盖所有的商业产品，发育候选药物，企业联盟的合作伙伴关系和制造支持。他持有the University of Health Sciences芝加哥医学院（ The Chicago Medical School）硕士学位；加利佛尼亚大学圣地亚哥分校（ University of California, San Diego） Rady管理学院工商管理硕士学位；以及加利佛尼亚大学洛杉矶分校（the University of California at Los Angeles）生物理学学士学位。
- Dennis D. Kim has served as our Chief Medical Officer since September 2011. From 2001 to 2012 Dr. Kim was an assistant professor of medicine, division of endocrinology/metabolism, at the University of California, San Diego School of Medicine. From September 2008 to February 2011 Dr. Kim held multiple senior-level clinical and corporate affairs positions at Orexigen Therapeutics, Inc. a publicly-traded biopharmaceutical company focused on the treatment of obesity, including senior vice president, head of obesity/metabolic diseases; senior vice president, corporate development; and senior vice president, medical affairs and communications. Prior to Orexigen, from September 2007 to September 2008 he was chief medical officer and vice president of medical affairs at EnteroMedics, Inc. a publicly traded medical device company, where he oversaw all aspects of clinical affairs and successfully implemented an initial public offering as part of the executive team in 2007. Previously, from July 2001 to September 2007 he held positions of increasing responsibility at Amylin Pharmaceuticals, Inc., a publicly traded biotechnology company, most recently as executive director, corporate strategy, where he managed corporate and business strategic planning spanning all commercial products, developmental drug candidates, corporate alliance partnership and manufacturing support. Dr. Kim holds an M.D. from the University of Health Sciences, The Chicago Medical School, an M.B.A from University of California, San Diego Rady School of Management and a B.S. in biology from the University of California at Los Angeles.
- Patricia L. Allen
Patricia L. Allen。 ， 自2013年1月起担任公司首席财务官。她在上市或者私人公司的生物技术行业有着20多年的金融领导经验。从2011年到2012年她为生物技术公司的多个领域提供独立咨询服务，包括担任代理首席财务官、筹款，交易结构，财务规划，组织结构，投资者关系及业务发展服务。之前，从2004年到2011年她担任Alnylam Pharmaceuticals金额副总裁、风险官和主要财务执行官，并积极参与投资界的互动；在通过该公司的首次公开募股、后续的普通股发行，以及与顶级制药公司多个业务发展交易筹集9亿美元活动中，她发挥了很大的作用。加入 Alnylam之前，她在Alkermes, Inc.工作，最近的职位是担任金额主管。她在Deloitte & Touche, LLP担任审计员开始自己的职业生涯。她以优异成绩毕业于Bryant College，持有工商管理理学学士学位。
Patricia L. Allen has served as a member of our board of directors and the chair of the audit committee since September 2016. Since 2013 Ms. Allen has served as Chief Financial Officer of Zafgen, Inc. Ms. Allen has over 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. From 2011 to 2012 she provided independent consulting services to biotechnology companies in a variety of areas, including interim chief financial officer services, fundraising, deal structures, financial planning, organizational structure, investor relations and business development. Previously, from 2004 to 2011 Ms. Allen served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly traded biotechnology company. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly traded biotechnology company, most recently as the Director of Finance. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen graduated summa cum laude from Bryant College with a B.S. in business administration.- Patricia L. Allen。 ， 自2013年1月起担任公司首席财务官。她在上市或者私人公司的生物技术行业有着20多年的金融领导经验。从2011年到2012年她为生物技术公司的多个领域提供独立咨询服务，包括担任代理首席财务官、筹款，交易结构，财务规划，组织结构，投资者关系及业务发展服务。之前，从2004年到2011年她担任Alnylam Pharmaceuticals金额副总裁、风险官和主要财务执行官，并积极参与投资界的互动；在通过该公司的首次公开募股、后续的普通股发行，以及与顶级制药公司多个业务发展交易筹集9亿美元活动中，她发挥了很大的作用。加入 Alnylam之前，她在Alkermes, Inc.工作，最近的职位是担任金额主管。她在Deloitte & Touche, LLP担任审计员开始自己的职业生涯。她以优异成绩毕业于Bryant College，持有工商管理理学学士学位。
- Patricia L. Allen has served as a member of our board of directors and the chair of the audit committee since September 2016. Since 2013 Ms. Allen has served as Chief Financial Officer of Zafgen, Inc. Ms. Allen has over 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. From 2011 to 2012 she provided independent consulting services to biotechnology companies in a variety of areas, including interim chief financial officer services, fundraising, deal structures, financial planning, organizational structure, investor relations and business development. Previously, from 2004 to 2011 Ms. Allen served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., a publicly traded biotechnology company. Prior to Alnylam, Ms. Allen was at Alkermes, Inc., a publicly traded biotechnology company, most recently as the Director of Finance. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen graduated summa cum laude from Bryant College with a B.S. in business administration.